A rapid liquid biopsy of lung cancer by separation and detection of exfoliated tumor cells from bronchoalveolar lavage fluid with a dual-layer “PERFECT” filter system

Tingyu Li1,#, Yaoping Liu1,2,#, Wei Zhang3, Lianjun Lin4, Jixin Zhang5, Yan Xiong5, Ligong Nie3, Xinmin Liu4, Haichao Li3,4, and Wei Wang1,6,7,#

1. Institute of Microelectronics, Peking University, Beijing, 100871, China;
2. Antimicrobial Resistance (AMR) and Critical Analytics for Manufacturing Personalized-Medicine (CAMP) IRG, Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore, 138602, Singapore;
3. Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China;
4. Department of Geriatrics, Peking University First Hospital, Beijing, 100034, China;
5. Department of Pathology, Peking University First Hospital, Beijing, 100034, China;
6. National Key Laboratory of Science and Technology on Micro/Nano Fabrication, Beijing, 100871, China;
7. Frontiers Science Center for Nano-optoelectronics, Peking University, Beijing, 100871, China.

# The two authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.01.25; Accepted: 2020.04.19; Published: 2020.05.17

Abstract

Separation and detection of exfoliated tumor cells (ETCs) from bronchoalveolar lavage fluid (BALF), namely the liquid biopsy of BALF, has been proved to be a valuable tool for the diagnosis of lung cancer. Herein, we established a rapid liquid biopsy of BALF based on a dual-layer PERFECT (precise, efficient, rapid, flexible, easy-to-operate, controllable and thin) filter system for the first time.

Methods: The dual-layer PERFECT filter system consists of an upper-layer filter with large micropores (feature size of 49.4 ± 0.5 μm) and a lower-layer filter with small micropores (9.1 ± 0.1 μm). The upper-layer filter contributes to the isolation of cell clusters and removal of mucus from BALF samples, meanwhile the lower-layer one targets for the separation of single ETCs. First, separation of 10000 spiked A549s (cultured lung cancer cells) from 10 mL clinical BALF samples (n=3) were performed to investigate the performance of the proposed system in rare cell separation. Furthermore, separation and detection of ETCs from clinical BALF samples were performed with this system to test its efficacy and compared with the routine cytocentrifuge.

Results: The recovery rate of spiked A549 cells from clinical BALF samples with the developed system (89.8 ± 5.2%) is significantly higher than that with the cytocentrifuge (13.6 ± 7.8%). In the preliminary clinical trial, although 33 clinical BALF samples with volume ranging from 6 mL to 18 mL showed greatly varied turbidity, filtrations could be finished within 3 min for 54.6% of samples (18/33), and 10 min at most for the rest. The dual-layer PERFECT filter system is proved to have a much higher sensitivity (80.0%, 95% CI: 55.7%−93.4%) than the routine cytocentrifuge (45.0%, 95% CI: 23.8%−68.0%), p=0.016 (McNemar test, two-tail). Moreover, the sensitivity of this platform is neither interfered by the variations of turbidity of the BALF samples, nor associated with the types of lung cancer.

Conclusions: The easy and rapid processing of BALF samples with varying volume and turbidity, competitive sensitivity and good versatility for different lung cancer types will make the established
dual-layer PERFECT filter system a promising approach for the liquid biopsy of BALF. The high-performance BALF-based liquid biopsy will improve the cytopathological identification and diagnosis of lung cancer.

Key words: lung cancer, liquid biopsy, exfoliated tumor cells (ETCs), bronchoalveolar lavage fluid (BALF), PERFECT filter

Introduction

Lung cancer is the deadliest malignancy with high incidence rates (11.6% worldwide, 13% in USA, 17% in China) and high mortality rates (18.4% worldwide, 23–24% in USA, 22% in China) among all kinds of cancers all over the world [1–3]. Five-year relative survival rate is only 5% for patients with lung cancer diagnosed at the advanced stage, while it significantly increases to 56% for those diagnosed at the early stage [2]. Therefore, early identification and diagnosis along with timely treatment has been acknowledged to be critical to improve the patient outcomes.

The present widely-used approaches for lung cancer diagnosis [4, 5] mainly include imaging screening and biopsy. Imaging methods, such as plain chest X ray, computerized tomography (CT) and positron emission tomography (PET), have obvious advantages of easy operation and no/low invasion. However, they are suffering a high false positive rate. For example, the false positive rate of low-dose computerized tomography (LDCT), a screening approach for high-risk lung cancer populations recommended by American Thoracic Society and American College of Chest Physicians (ATS and ACCP) [6], is as high as 96.4% [7, 8], which may lead to unnecessary follow-up examinations and cause anxiety and panic to patients. Sampling from lesions and conducting pathological examinations, is the only standard for the final identification and diagnosis of lung cancer in clinical practices. Pathology can be divided into histopathology and cytopathology according to the types of examined specimens (tissues and cells), which correspond to tissue biopsy and liquid biopsy, respectively. Histopathology has been conventionally used as the gold standard, considering adequate tumor contents can be obtained in the tissue biopsy via surgery or imaging-guided needling, and thereby can provide more information for identification of tumor stage and grade. However, the sampling procedures are more invasive and riskier to complications, and even unavailable for those in poor physical condition. For liquid biopsy, although the sensitivity and specificity of cytological examination are variable among different specimen sources and different handling methods, the benefits of liquid biopsy including minimal invasiveness, rapidness and ease of repeatable tests are clear in terms of patient acceptability and disease management. Liquid biopsies can complement the tissue biopsy, allowing more patients to be tested, and thus are worth exploring. Extensive attentions and efforts have been devoted to developing advanced strategies to promote applications of liquid biopsy in clinical practices during the last decade [9–12].

As for the liquid biopsy of lung cancer, besides the recent mainstream blood-based test, the cytological examination of bronchoalveolar lavage fluid (BALF) has been an adopted diagnostic method for lung cancer in hospitals since 1980s [13, 14]. However, the presently used cytological examination approaches suffer a low detection sensitivity, which degrades the application value of BALF in lung cancer diagnosis. The conventional approaches can be mainly classified into two types: centrifugation-based and filtration-based methods, with SurePath and CYTOfast, track-etched membrane and Thinprep as typical commercial products, respectively [15]. The centrifugation-based methods are the most commonly used methods for cell recovery from liquid sample but always result in considerable cell loss. The filtration-based methods are applied via separating the larger target cells from smaller background cells. However, the filters embedded in the existing commercial products are of low porosity, non-uniform pore size and non-uniform pore-to-pore space, which lead to easily-happened clogging (i.e. limited volume sample to be operated) and insufficient cell recovery ability. The previously reported diagnostic sensitivities of BALF for lung cancer based on the conventional methods range from 7% (peripheral lesions < 2 cm) to 50% (central lesions > 3 cm). Clearly, the sensitivity and diagnostic efficacy of BALF was influenced by the size and segmental location of the lesion [4, 16–19]. The low sensitivities are attributed to two factors: the cell loss and the limited sample volume operation capability by the aforementioned methodologies for exfoliated tumor cells (ETCs) separation and detection from BALF. Therefore, to promote the use of BALF-based liquid biopsy of in the clinical diagnosis of lung cancer, the key is increasing the separation efficiency and detection sensitivity of rare ETCs at a high operation
throughput from large-volume samples.

In recent years, with the involvement of micro/nanotechnology, the capability of rare cell recovery from clinical fluids has been significantly improved. Various liquid biopsy techniques have been reported, including microfluidics-based (cell-affinity micro-chromatography [20–23], hydrodynamic microfluidics [24–26], other cell physical properties [27–29], etc.) and filtration-based techniques (micropillar [20, 30], microweir [31], micropore [32–34]). The filtration-based liquid biopsy has been well acknowledged to be promising for achieving a high throughput and thus handling large-volume clinical samples. A lot of micropore-arrayed filters [32–34] with uniform pore size and pore-to-pore space have been achieved with advanced micro/nano fabrications and have realized high-efficiency cell recovery during the past decade. However, the porosities of those filters are still low and only realize a filtration throughput not higher than 2 mL/min, which cannot fulfill the process of large-volume BALF samples, although is sufficient for liquid biopsy of blood. A high-porosity PERFECT (precise, efficient, rapid, flexible, easy-to-operate, controllable and thin) filter for efficient rare cell separation from large-volume samples at a high throughput (>110 mL/min for aqueous sample, >17 mL/min for undiluted whole blood, only driven by the gravity) has been established in our previous work [35]. And a high recovery rate of 86.0 ± 5.3% for the detection of ~10 spiked cultured lung cancer cells (A549s) from 10 mL non-cancer BALF samples with a PERFECT filter with micropores of feature size at 9.1 ± 0.1 μm (Filter-1 as listed in Table 1) has been verified. However, BALF samples from lung cancer patients are more complex with contents of mucus, ETCs, ETC clusters, epithelial cells, leukocytes, erythrocytes, etc. Clogging problem exists in the single-layer PERFECT filtration of most BALF samples. In addition, the ETC clusters are thought to be more metastatic and of important value for tumor monitoring, and worth efforts to separate and detect, which was not involved in our previously preliminary work. This work proposes a dual-layer PERFECT filter system for ETC (cluster) separation and detection from raw BALF samples. Two filters with different feature sizes are assembled into the working system. The upper-layer filter contains larger micropores (feature size at 49.4 ± 0.5 μm, Filter-3 as listed in Table 1) for the separation of ETC clusters and removal of mucus, while the lower-layer one contains smaller micropores (9.1 ± 0.1 μm, Filter-1 as listed in Table 1) for the separation of rare single ETCs. The choice of upper-layer feature size is systematically investigated and optimized in this work, and the decision of lower-layer feature size is according to our previous work verifying efficient recovery of rarely spiked A549 from BALF samples [35]. Moreover, to demonstrate the efficacy of the developed dual-layer PERFECT filter system, a preliminary clinical trial containing 33 BALF samples from patients with visible lesions under bronchoscope was performed, with the routine approach as a parallel comparison.

| Table 1. Feature sizes and porosities of the PERFECT filters used in this work. |
|---|---|---|---|---|
| Case No. | Designed value (μm) | Practical value (μm) | Porosity (%) |
| | d | s | d | s | P |
| PERFECT Filter-1 | 100 | 4 | 9.1 ± 0.1 | 4.7 ± 0.2 | 46.7 |
| PERFECT Filter-2 | 25 | 4 | 24.5 ± 0.1 | 4.5 ± 0.1 | 71.5 |
| PERFECT Filter-3 | 50 | 4 | 49.4 ± 0.5 | 4.6 ± 0.1 | 83.8 |
| PERFECT Filter-4 | 100 | 4 | 99.4 ± 0.5 | 4.5 ± 0.1 | 91.4 |

**Methods**

**Set-up of dual-layer PERFECT filter system**

The BALF samples are of complex contents, including mucus, ETCs, ETC clusters, epithelial cells, leukocytes and erythrocytes. A dual-layer filtration system is proposed here for effective ETC (cluster) separation from raw BALF samples, schematically shown in Figure 1A-B. The ETC clusters and mucus are collected on the upper-layer filter. The single ETCs, large epithelial cells and leukocytes are captured on the lower-layer filter. The small epithelial cells, leukocytes and erythrocytes together with the fluid passed through the filters and are collected in the waste tube.

To decide the feature size of the upper-layer filter, filters with different micropore diameters (Filter-2, -3 and -4 as listed in Table 1) were experimentally investigated to optimize the filtration performance. The selection of lower-layer filter (Filter-1 as listed in Table 1) is from the optimized results of our previous related work [35], for the efficient recovery of single ETCs. The feature sizes, including the diagonal length (d) and space between adjacent micropores (s), and porosities (p) of PERFECT filters used in this work are listed in Table 1.

The PERFECT filters were fabricated with our previously reported Parylene C molding technique [36]. The photos and typical scanning electron microscopy (SEM) images of the upper-layer filter and lower-layer filter are displayed in Figure 1C, E and D, F, respectively. As shown in Figure 1G, the upper-layer filter and lower-layer filter were sequentially packaged from top to bottom and assembled into the working system with the home-designed Teflon gadgets, for filtration of BALF samples. The sealing of filters, clamp of Teflon
gadgets, was simply but effectively achieved with two ring magnets.

The routine cytological test currently used in hospitals

All clinical BALF samples were processed in parallel with a hospital-used cytocentrifuge for liquid-based cytology as comparison. The cytocentrifuge system used in this study, as displayed in Figure 1H-I, was purchased from Hettich (ROTOFIX32A), Germany. Briefly, the BALF sample with according volume for each case was loaded into the sample cup, as shown in Figure 1I, with an upper limit of 10 mL, which was decided by the cell density predicted with the nephelometric reading, to guarantee a monolayer of cells for the convenience of observation under microscopy and accuracy of cytological recognition. Centrifugation at 2000 rpm for 10 min was applied, and the supernatant was discarded, followed by staining and reading of the collected cells on the slides.

Patient inclusion criteria

The inclusion criteria of clinical cases in the present work were that the patients were suspected of having lung cancer and reached the requirement of bronchoscopy test, plus with visible lesions under bronchoscope. From November, 2017 to June, 2018, 33 patients who were highly suspected as lung cancer and required bronchoscopy evaluation were enrolled in this study in the Peking University First Hospital. As a blind test, the patient status (having malignant or benign tumor) was not disclosed to the operators during the BALF sample collection, process and pathological assessment. The final histopathological diagnosis results revealed that, 20 cases are malignant tumors while the other 13 cases are benign tumors.

Collection and preservation of BALF samples

Collection of BALF samples was approved by the ethics board committees and signed by the chairman of the committee of in the Peking University First Hospital (Approved No.: 2017-1385). Informed consents were obtained from patients for all the experimentations.

Figure 1. (A, B) Schematic illustration of the working principle of the present dual-layer PERFECT filter system for the ETC (cluster) separation from BALF samples. (C, D) The photos and (E, F) SEM images of the upper-layer filter with large micropores and lower-layer filter with small micropores (Filter-3 and Filter-1 as listed in Table 1, respectively). Scale bars represent 20 μm in E, F. (G) The assembled dual-layer filter system, with home-designed Teflon gadgets and ring magnets for interconnection and sealing. (H, I) The cytocentrifuge used as a parallel comparison in this work.
The BALF samples were collected during the operation of bronchoalveolar lavage (BAL) performed in the lesion area of interest, in compliance with the relevant laws and institutional guidelines (Good Clinical Practice (GCP) of China). BAL was performed under general anesthesia. After a thorough inspection of the airway, warm normal saline was instilled into the target segment and collected via suction. The obtained BALF samples (about 12-36 mL) were stored in 4 °C and processed within 6 h with the present dual-layer PERFECT filter system and the cytocentrifuge in parallel. Tissue biopsies were also performed. Final diagnoses of malignancies were confirmed by histopathological results.

**Verification of ETC separation with spiking BALF samples**

To verify the recovery rate of this dual-layer PERFECT filter system, spiking BALF samples were first tested. The spiking samples were prepared by adding 10000 A549 cells (purchased from the National Infrastructure of Cell Line Resource, Beijing, China) via serial dilutions into 10 mL BALF samples. A549s were pre-labeled with Cell Tracker Green (5 μM, C2925, Invitrogen™, Thermo Fisher, USA) and Hoechst 33342 (5 μg/mL, H1399, Invitrogen™, Thermo Fisher, USA), in order to facilitate the observation and counting of the recovered A549s among background cells from BALF under the fluorescence microscope (CKX53, Olympus, Japan). Separation of A549 cells from the spiking samples were carried out via the dual-layer PERFECT filter system, single-layer PERFECT filter and the cytocentrifuge, in parallel. After filtration and centrifugation, the separated cells on filters were mounted between glass slides and cover slips with the Antifade Mountant (P36961, Invitrogen™, Thermo Fisher, USA), observed and double-interpreted by two experienced pathologists from the department of pathology, Peking University First Hospital, according to cytological guidelines [19, 37, 38].

**Statistical analysis**

The cytopathological results from both the present dual-layer PERFECT filter system and the cytocentrifuge were compared with the routinely used gold standard, histopathological results, to verify the sensitivity and specificity. The 95% confidence intervals (95% CI) for sensitivity were calculated. McNemar test was used to compare the disagreement of sensitivities between the dual-layer PERFECT filter system and the cytocentrifuge in the cytological diagnosis of BALF. Kappa test was carried out to evaluate the agreement between the histopathological diagnosis and BALF-based cytological diagnosis, including the dual-layer filtration-based and cytocentrifuge-based approaches. Statistical analyses were performed using VassarStats: Website for Statistical Computation [39].

**Results and Discussion**

**Optimization of the dual-layer PERFECT filter system with spiking BALF samples**

Filter-1 was used as the lower layer because of its verified high recovery rate in our previous work [35] for the recovery of rarely spiked A549s from 10 mL clinical BALF samples. In the previous work, the non-cancer BALF samples were of clear appearances with few mucus. However, BALF samples from lung cancer patients were more complex and easily to form clogging if only filtered with the Filter-1, which led to a low throughput and a low detection sensitivity. To address this issue, hereby a dual-layer PERFECT filter system was designed, which consists of an upper-layer and a lower-layer PERFECT filter for the removal of mucus and isolation of cell clusters, and the recovery of single ETCs, respectively. To optimize the feature size of upper-layer PERFECT filter, a BALF sample was divided in to three aliquots, and filtered through three different filters (Filter-2, -3 and -4). The filtration results are shown in Figure 2A-C. Filter-2 with micropores of feature size at 24.5 ± 0.1 μm and porosity at 71.5% still suffered the mucus blocking...
issue, leading to a low throughput. Filter-4 with micropores of feature size at 99.4 ± 0.5 μm and porosity at 91.4% is of a low mechanical strength, and was easily deformed even when the filter was only partially clogged. Filter-3 with micropores of feature size at 49.4 ± 0.5 μm and porosity at 83.8% showed a good compromise between the throughput and mechanical strength for the filtration of raw BALF samples with complex contents. Therefore, the following dual-layer PERFECT filter system used for clinical trial was implemented with Filter-3 and Filter-1 as the upper layer and lower layer, respectively.

Recovery results of spiked A549 cells (10000) from BALF samples with dual-layer (Filter-3 and Filter-1, sequentially), single-layer (Filter-3 only and Filter-1 only) and cytocentrifuge were compared in Figure 2D. The dual-layer PERFECT filter system (Filter-3 + Filter-1) achieved a high recovery rate of 89.8 ± 5.2% (i.e. the ratio of the number of recovered A549 cells on the Filter-3 plus that on the Filter-1 to the total number of spiked A549 cells), with 6.7 ± 5.7% and 83.1 ± 10.6% of spiked A549s recovered on the Filter-3 and Filter-1, respectively. Typical fluorescent images of separated A549s on Filter-3 and Filter-1 through dual-layer filtration are shown in Figure 2E–F. The diameter of A549 is 12.8 ± 2.5 μm from our measurements, and it is much smaller than the feature size of micropores in Filter-3 (diagonal length of 49.4 ± 0.5 μm), while larger than that of Filter-1 (diagonal length of 9.1 ± 0.1 μm). Therefore, 83.1 ± 10.6% of the spiked single A549 cells passed through the Filter-3 and were subsequently recovered on the Filter-1. There were 6.7 ± 5.7% A549 cells recovered on the Filter-3 because of the adhesion onto the large-sized mucus. The single-layer filtration through Filter-3 only presented a low recovery rate of 5.4 ± 4.7%, similar to that of the upper-layer Filter-3 in the dual-layer PERFECT filter system. Meanwhile, the single-layer filtration through Filter-1 had a recovery rate of 56.1 ± 11.5%, which was much lower than that of the Filter-1 used as the lower layer in the dual-layer PERFECT filter system. It is because that mucus in the BALF samples easily blocked most area of the Filter-1, and failed the operation of the whole sample, and thus caused most of A549 cells to be lost with the disposed supernatant. The dual-layer PERFECT filter system presents a dramatically improved performance in the recovery of rare targeted cells from BALF samples, compared to the single-layer filtrations. However, the cytocentrifuge as the comparison presents a low recovery rate of 13.6 ± 7.8% (Figure 2G). The low recovery rate of the cytocentrifuge was attributed to that most of A549 cells were discarded with the supernatant after centrifugation. The results indicated that the proposed dual-layer PERFECT filter system fulfills a significantly higher recovery rate of A549 cells than the traditionally used cytocentrifuge, and thereby holds promising potential to improve the sensitivity of the diagnosis of lung cancer with BALF as specimens.

Separation and detection of ETCs (clusters) from raw BALF samples

High filtration throughput of the dual-layer PERFECT filter system

33 patients with visible lesions under bronchoscope were enrolled in the preliminary clinical trial of this study, with the detailed information of patients listed in Table 2. The BALF samples collected from patients were of great variances, especially in terms of turbidity (the content percentage of mucus) and volume, which might strongly influence the filtration performance. In this work, the collected BALF samples with volume of 12–36 mL were divided into two aliquots, with one processed with the dual-layer filtration system and the other one with the conventionally used cytocentrifuge. The turbidity of the 33 samples was classified into three grades: clear (+) for 11 samples, slightly turbid (++) for 13 samples, and extremely turbid (+++) for 9 samples, according to the mucus content percentages from the appearance, with typical photos of different turbidity grades displayed in the insets of Figure 3A.

All the BALF samples with volume of 6–18 mL can be operated within 10 min with the dual-layer PERFECT filter system. It enables a short time-to-result (<30 min) from obtaining the sample to reporting the diagnosis result, together with the HE staining (~10 min) and manual cytological interpretation (~10 min). Average throughputs for clear (31.9 ± 17.3 mL/min), slightly turbid (3.2 ± 2.6 mL/min) and extremely turbid (<0.5 mL/min) BALF samples were shown in Figure 3A. The results indicated that the lower turbidity of BALF, the higher throughput. Clear (11/33) and slightly turbid (13/33) BALF samples were filtrated smoothly and completely. Among them, 54.6% BALF specimens (18/33) were filtrated within 3 min, and others could be finished completely within 10 min. However, clogging by mucus still happened in the extremely turbid BALF samples (9/33), which hindered the whole samples going through the filters. For these cases, the filtrations were stopped by discarding the unfiltered sample when it consumed up to 10 min (filtration time was recorded as >600 s in Table 2). Even so, our system still can recover sufficient cells for diagnosis, which will be further discussed in the
following sections. Typical photos of the three graded BALF samples before filtration and the appearance of Filter-3 after filtration were shown as the insets in Figure 3A.

Figure 3B shows the real-time throughputs of three clear and two slightly turbid BALF samples. All the five samples showed high throughputs at the beginning, and throughputs gradually decreased along with the mucus blocking and cell accumulating on the PERFECT filters. Pretreatment of digestion to remove mucus in the turbid BALF samples could be an option to facilitate an improved filtration throughput, and will be investigated and optimized in future.

Table 2. The diagnostic results of clinical BALF specimens by the dual-layer PERFECT filter system and the cytocentrifuge, compared to the definitive diagnosis from histopathological results.

| Patient description | Sample description | Dual-layer PERFECT filter system | Cytocentrifuge result | Histopathological diagnostic result |
|---------------------|--------------------|----------------------------------|-----------------------|-------------------------------------|
| No. | Sex | Age | Volume (mL) | Turbidity | Time (s) | Throughput (mL/min) | Result | Result | Result |
|-----|-----|-----|-------------|-----------|---------|-------------------|-------|--------|--------|
| 1   | F   | 48  | 6.0         | +         | 5       | 72.0              | NEG   | NEG    | CTD-ILD |
| 2   | F   | 50  | 7.5         | +         | 10      | 45.0              | NEG   | NEG    | Sarcoïdosis |
| 3   | F   | 57  | 6.0         | +         | 8       | 45.0              | NEG   | NEG    | Mediastinal fibrosis |
| 4   | F   | 61  | 10.0        | +         | 15      | 40.0              | NEG   | NEG    | Pneumonia |
| 5   | M   | 64  | 14.0        | +         | 25      | 33.6              | SCC   | SCC    | SCC    |
| 6   | F   | 33  | 14.0        | +         | 26      | 32.3              | ADC   | NEG    | ADC    |
| 7   | M   | 53  | 8.0         | +         | 17      | 28.2              | NEG   | NEG    | Tuberculosis |
| 8   | F   | 77  | 12.0        | +         | 30      | 24.0              | NEG   | NEG    | Tuberculosis |
| 9   | M   | 46  | 10.0        | +         | 25      | 24.0              | ADC   | NEG    | ADC    |
| 10  | F   | 57  | 10.0        | +         | 40      | 15.0              | NEG   | NEG    | ADC    |
| 11  | M   | 65  | 11.0        | +         | 50      | 13.2              | SCC   | NEG    | SCC    |
| 12  | M   | 58  | 10.0        | ++        | 60      | 10.0              | NEG   | NEG    | Metastatic cancer |
| 13  | M   | 80  | 6.5         | ++        | 40      | 9.8               | SCC   | SCC    | SCC    |
| 14  | M   | 36  | 13.0        | ++        | 150     | 5.2               | NEG   | NEG    | Sarcoïdosis |
| 15  | M   | 50  | 10.0        | ++        | 120     | 5.0               | ADC   | ADC    | ADC    |
| 16  | M   | 58  | 6.5         | ++        | 90      | 4.3               | NEG   | NEG    | SCC    |
| 17  | M   | 63  | 7.0         | ++        | 150     | 2.8               | SCLC  | NEG    | SCLC   |
| 18  | M   | 47  | 10.0        | ++        | 240     | 2.5               | NEG   | NEG    | Lung abscess |
| 19  | M   | 56  | 6.5         | ++        | 180     | 2.2               | NEG   | NEG    | Inflammation |
| 20  | F   | 67  | 12.5        | ++        | 360     | 2.1               | NEG   | NEG    | Old lesion |
| 21  | M   | 40  | 14.0        | ++        | 420     | 2.0               | NEG   | NEG    | Sarcoïdosis |
| 22  | M   | 60  | 10.0        | ++        | 420     | 1.4               | SCC   | NEG    | SCC    |
| 23  | F   | 43  | 12.0        | ++        | 600     | 1.2               | ADC   | ADC    | ADC    |
| 24  | M   | 68  | 10.0        | ++        | 600     | 1.0               | NEG   | NEG    | IPF    |
| 25  | M   | 69  | 9.0         | +++       | >600    | <0.5              | NEG   | NEG    | Infection |
| 26  | M   | 54  | 16.0        | +++       | >600    | <0.5              | SCLC  | SCLC   | SCLC   |
| 27  | M   | 46  | 12.0        | +++       | >600    | <0.5              | ADC   | NEG    | ADC    |
| 28  | F   | 47  | 12.0        | +++       | >600    | <0.5              | ADC   | NEG    | Metastatic cancer |
| 29  | M   | 66  | 18.0        | +++       | >600    | <0.5              | SCC   | SCC    | SCC    |
| 30  | F   | 44  | 6.0         | +++       | >600    | <0.5              | SCLC  | SCLC   | SCLC   |
| 31  | M   | 71  | 12.0        | +++       | >600    | <0.5              | SUS   | SUS    | Metastatic cancer |
| 32  | M   | 68  | 8.0         | +++       | >600    | <0.5              | NEG   | NEG    | SCC    |
| 33  | M   | 56  | 13.0        | +++       | >600    | <0.5              | SCC   | SUS    | SCC    |

NEG: negative for neoplastic cells; SCC: squamous cell carcinoma; ADC: adenocarcinoma; SCLC: small cell lung cancer; SUS: suspected for neoplastic cells; CTD-ILD: connective tissue disease-associated interstitial lung disease; IPF: idiopathic pulmonary fibrosis.

Volume*: half of the totally collected volume was allotted for each method.

Legend:
- True positive with the dual-layer PERFECT filter system and false negative with the cytocentrifuge;
- True positive with both the dual-layer PERFECT filter system and cytocentrifuge;
- False negative with both the dual-layer PERFECT filter system and cytocentrifuge;
- True negative with both the dual-layer PERFECT filter system and cytocentrifuge.
Figure 2. (A–C) The photos of PERFECT filter-2, -3 and -4 after filtration of BALF. (D) The recovery rates of 10000 pre-labeled A549 cells spiked in 10 mL BALF with the dual-layer (Filter-3 and Filter-1, sequentially), single-layer (Filter-3 only), single-layer (Filter-1 only) and cytocentrifuge, respectively. (E–F) The images of separated A549 cells on the Filter-3 and Filter-1 through the dual-layer filtration. (G) The images of separated A549 cells on the glass slide after centrifugation. Scale bars represent 100 μm in E–G.

Figure 3. (A) Average filtration throughputs of the three graded BALF samples with different turbidity with the dual-layer PERFECT filter system. Insets showed the photos of typical BALF samples before filtration and the Filter-3 after filtration to give a visual sense of the differently graded turbidity. (B) Real-time throughputs of the typical clear BALF samples (#05, #09 and #10) and slightly turbid BALF samples (#12 and #14). Insets showed the appearance of these typical BALF samples.

High detection sensitivity and specificity of the dual-layer PERFECT filter system

Among the enrolled 33 patients, 20 cases were finally diagnosed as lung cancer positive while the other 13 patients were negative according to histopathological results. As shown in Figure 4A, the sensitivity of the present dual-layer PERFECT filter system is 80.0% (16/20) with 95% CI of 55.7%–93.4%, while that of the cytocentrifuge is only 45.0% (9/20) with 95% CI of 23.8%–68.0%. In the McNemar test, the calculated $p=0.016$ (two-tail) indicates that the BALF diagnosis using the dual-layer PERFECT filter system is significantly advantageous than using the cytocentrifuge. All the lung cancer negative BALF samples were all correctly diagnosed by the two approaches, presenting a high specificity of 100%. As shown in Figure 4B, the dual-layer PERFECT filter system presents false negative results in 4 cases, which is significantly lower than that from the cytocentrifuge (11 cases), for the samples (20 cases) diagnosed to be lung cancer positive according to the histopathological results. The Kappa test shows the dual-layer PERFECT filter system ($κ=0.759$) has better agreement than the cytocentrifuge ($κ=0.392$), compared with the histopathological diagnosis.

The key for high detection sensitivity of the developed dual-layer filtration system in the separation and detection of ETCs from large-volume BALF samples is that it can fulfill a high throughput of sample operation and a high recovery efficiency of rare cells, simultaneously. However, the centrifugation-based approaches [17, 18] can only realize a high throughput while suffer low cell
recovery efficiency. The micro/nano technique-based approaches [20–34], are promising to achieve a high cell recovery efficiency but suffer a low throughput, and thus fail to process large-volume clinical samples.

The BALF-based diagnosis should be more competitive in the diagnosis of peripheral lung cancer, because the BAL operation has access to the peripheral pulmonary lesions where the bronchoscopy can’t reach [13]. Bigger differences in sensitivity between the developed dual-layer PERFECT filter system and the cytocentrifuge, i.e. more prominent advantages of filtration, are anticipated in further multi-institutional clinical trials with recruitments of patients with small lung nodules under CT. The developed system will be promising to advance the cytological test of small nodules and fulfill the diagnosis of early lung cancer.

All BALF samples with three turbidity grades can be diagnosed effectively with the dual-layer PERFECT filter system. Figure 4C shows the sensitivities of all the three graded turbid samples with the PERFECT filter system are of no big difference, with 80.0% (4/5), 71.4% (5/7) and 87.5% (7/8) for 5 positive cases in clear group, 7 positive cases in slightly turbid group and 8 cases in extremely turbid group, respectively, being correctly diagnosed with the dual-layer PERFECT filter system. However, those values from the conventional cytocentrifuge are only 20.0% (1/5), 42.9% (3/7) and 62.5% (5/8), which are much lower than the dual-layer filtration method. For the clear and slightly turbid groups, filtration of the whole samples could finish smoothly without clogging, plus the high recovery efficiency of the PERFECT filter, therefore, higher sensitivities were achieved with the established dual-layer PERFECT filter system. While, the cytocentrifuge suffered cell loss from centrifugation and a limited operated sample volume as aforementioned, and thus presented relatively lower sensitivities. For the extremely turbid group, even though clogging happened and caused not the whole sample to be filtered (with unfiltered part discarded after an utmost filtration duration of 10 min), there still presented a higher sensitivity at 87.5% (7/8) with the dual-layer PERFECT filter system, compared to that (62.5% (5/8)) with the cytocentrifuge. The detailed reason for this merit will be further investigated. And also, pretreatment of the extremely turbid samples to fulfill higher-performance filtration and diagnosis is a worth noting direction to go in the further clinical trials. Besides, it seems that the sensitivity has a relationship with the turbidity grade. First, the sensitivities of clear, slightly turbid, extremely turbid samples are 45.5% (5/11), 53.9% (7/13) and 88.9% (8/9), respectively. On the other hand, the proportions of clear, slightly turbid, extremely turbid samples in the 20 correctly-diagnosed positive cases are 25.0% (5/20), 35.0% (7/20) and 40.0% (8/20), respectively. While the reason is not clear and we will try to investigate in future and hope to be able to report soon.

Moreover, the dual-layer PERFECT filter system is generally applicable to different types of lung cancer. As shown in Figure 4D, the 20 positive lung cancer cases in this trial include 8 cases of squamous cell carcinoma (SCC), 6 cases of adenocarcinoma (ADC), 3 cases of small cell lung cancer (SCLC) and 3 cases of metastatic cancer (metastasis from a non-lung primary carcinoma to the lung). The sensitivities with the proposed system are 75.0% (6/8), 83.3% (5/6), 100% (3/3) and 66.7% (2/3) for SCC, ADC, SCLC and metastatic cancer, respectively. However, those with the cytocentrifuge are only 50.0% (4/8), 33.3% (2/6), 66.7% (2/3) and 33.3% (1/3). It is easy to notice that there is the biggest difference between the dual-layer PERFECT filter system (83.3%) and the cytocentrifuge (33.3%) for the ADC type. This could be attributed to that ETCs from ADC patients usually appear in clusters [40], which are more easily enriched and recovered by Filter-3.

In the 16 positive cases diagnosed with the dual-layer PERFECT filter system, the ETCs were identified mainly on the upper-layer (Filter-3), although the recovery rate of A549s from spiking sample on the upper-layer (Filter-3) is as low as 6.7 ± 5.7% shown in Figure 2. The much higher positive detection rate could be attributed to that single A549 cells in the spiking samples is much smaller than the pore size of Filter-3 and passes through the Filter-3 easily, while ETCs in patient BALF samples usually appear in clusters or adhere to mucus and are more likely to be recovered on Filter-3. Typical images of cells/clusters recovered on the PERFECT filters and slides after centrifugation are displayed in comparison in Figure 4E–G. More ETCs (clusters) in more concentrated distributions are presented on the filters than on the slides, which can be attributed to both recovery and enrichment of target cells/clusters with the PERFECT filter system and its large operable volume of BALF samples. The established dual-layer filtration ensures most of small normal cells such as squamous cells, erythrocytes, lymphocytes, granulocytes, etc., pass through the PERFECT filters, and thereby enrich the large, usually abnormal cells, besides macrophages. The large number and concentrated distribution of ETCs (clusters) will contribute to worth-expecting higher accuracy and diagnostic efficiency for the pathologists in clinical applications. Therefore, the PERFECT filter system can guarantee a clear view of cells on the PERFECT
filters for an easy and rapid identification of the abnormal cells even after process of the whole BALF samples with a large volume and a large number of cells. On the contrary, the cytocentrifuge leads cells to pile up on the slides when the cell number is over the specific criteria in most clinical cases because of no selectivity of cells. To guarantee a monolayer of cells on slides, only a limited volume according to the pretested cell density in the sample, usually less than 10 mL, can be loaded into the Hettich sample cup based on the pre-measured cell concentration. The smaller operable sample volume is the leading reason for a lower cell recovery rate for the cytocentrifuge, compared to the PERFECT filter system. And the great dispersion of the rare ETCs increases the difficulty of identification and diagnostic efficiency for the pathologists. Overall, the developed dual-layer PERFECT filter system fulfills an efficient liquid biopsy of BALF targeted for lung cancer, and is well worth promoting through more clinical trials to advance its final practical applications.

Feasibility of large-field scanning imaging for promising AI-assisted interpretation

After the HE staining, PERFECT filters with recovered cells (clusters) were mounted by glass slides. The thickness of the filter is only about 10 μm, i.e. about the diameter of an individual cell. The filters with recovered cells after filtration are flat enough for direct reading, benefiting from a high mechanical strength [36]. The above two advantages guarantee a high quality of scanning imaging over the whole effective filtration area (12 mm in diameter) of PERFECT filters, as shown in Figure 5. This facilitates a promising automatic interpretation of tumor cells with the rapid development of the artificial intelligence enabled image recognition technology. It’s worthy of mentioning that the pathological interpretation based on machine learning might be a promising way to avoid the variations from different operators or physicians.

Figure 4. (A) Higher sensitivity of the established dual-layer PERFECT filter system (80.0%) than that of the cytocentrifuge (45.0%). (B) The specifically lung cancer positive and negative case numbers of all 33 samples with the dual-layer PERFECT filter system and the cytocentrifuge. (C) The sensitivities of all the three graded turbidity samples with the dual-layer PERFECT filter system are higher than those with cytocentrifuge. (D) The sensitivities of all the lung cancer types with the dual-layer PERFECT filter system are higher than those with the cytocentrifuge. (E-G) The ETC clusters and ETCs circled with red dashed lines on the upper-layer PERFECT filter, lower-layer PERFECT filter and the slide after centrifugation. Scale bars represent 100 μm in E-G.
Compatibility and feasibility for various downstream analyses

The HE staining-based cytology used in the present work is a routine approach in the department of pathology in hospitals, and can fulfill the preliminary interpretation. While, the diagnostic efficiency and accuracy largely depend on the experience of the pathologist to distinguish the tumor cells from lots of background cells. Therefore, further downstream analyses, such as immunocytochemistry (ICC), immunofluorescence (IF), fluorescent in situ hybridization (FISH), mass spectrum, sequencing, etc., of the ETCs are important and worth doing to provide more information to fulfill further precise diagnosis and provide guide for personalized therapy. In situ assays (ICC, IF and FISH) are feasible with recovered cells staying on the PERFECT filters. Meanwhile, the mass spectrum and sequencing raise the requirement for cell release from the filters, which has been proved to be feasible.

Moreover, ETCs from BALF are thought to be able to reveal more information about the primary tumor site [41-43] than the present mainstream circulating biomarkers from peripheral blood, such as circulating tumor cells (CTCs) [44, 45] and circulating tumor DNA (ctDNA) [46, 47]. In addition, there are increasing controversies about the discordancy between the blood-based liquid biopsy and tissue biopsy recently [48], and the genetic alterations have been also increasingly reported in controls, such as clonal hematopoiesis [49-51]. These questionable points may hamper the specificity of non-invasive blood-based tests. Notably, results of proteomic and genomic analyses from several studies [52-55] support the conclusion that the BALF more than serum (blood-based) reflects the lung cancer. Above all, BALF is a promising source for liquid biopsy of lung cancer, and exfoliated cells are the valuable detection targets as intact cells containing both proteinic and genetic contents for comprehensive downstream analyses.

Conclusions

In this work, a high-efficiency liquid biopsy platform based on a dual-layer PERFECT filter system for rapid and sensitive separation and detection of ETCs from BALF samples is successfully developed. The ETC clusters and single ETCs have been efficiently recovered by the upper-layer filter with large micropores (feature size of 49.4 ± 0.5 μm) and the lower-layer filter with small micropores (9.1 ± 0.1 μm), respectively, followed by an in-situ HE staining for cytopathological identification. In the preliminary clinical trial including 20 lung cancer positive and 13 lung cancer negative cases, according to the histopathological diagnosis, a higher sensitivity (80.0%, 95% CI: 55.7%-93.4%) has been achieved with the established dual-layer PERFECT filter system, which is nearly double of that (45.0%, 95% CI: 23.8%-68.0%) obtained with the traditional cytocentrifuge, with p-value of 0.016 (McNemar test, two-tail). Both the dual-layer PERFECT filter system and cytocentrifuge present 100% specificity. Besides the high detection sensitivity and specificity, the developed system enables a short time-to-result, benefiting from the handling ability of large-volume (6-18 mL in this study) clinical BALF samples with complex contents at a high filtration throughput. The filtration of clinical BALF samples were finished within 3 min for 54.6% samples (18/33) and 10 min at most for the rest ones, with throughputs of 31.9 ± 17.3
mL/min and 3.2 ± 2.6 mL/min for clear and slightly turbid samples, respectively. Although the extremely turbid samples with filtration throughput of less than 0.5 mL/min, the PERFECT filter system still fulfill the diagnosis at a high sensitivity of 87.5% (7/8). Moreover, the handiness in system set-up, ease of operation and readiness for integration with various downstream analysis will facilitate the developed system to find wide applications in clinical practices.

The established dual-layer PERFECT system has demonstrated the detection of rare ETCs from BALF samples with a high detection sensitivity and promotes the clinical significance of liquid biopsy of BALF for lung cancer diagnosis. Thanks to the easier accessibility of BALF sampling than the tissue biopsy, the efficient and sensitive liquid biopsy of BALF is thought to be more advantageous in the peripheral lung cancer. The investigation of the dual-layer PERFECT filter system application in peripheral pulmonary lesions will be the key focus of the follow-up study, mainly with BALF samples from patients of small lung nodules under CT to be enrolled via a multi-institutional trial. That will be promising to advance the cytological test of nodules and fulfill the diagnosis of early lung cancer. Even more noteworthy is that the established dual-layer PERFECT filter system is feasible to be adjusted and find powerful uses in efficient separation and detection of rare tumor cells, fungi and bacteria from various samples such as blood, urine, sputum etc., for different clinical applications to further expand the social and economic benefits.

Abbreviations

PERFECT filter: precise, efficient, rapid, flexible, easy-to-operate, controllable and thin filter; ETC: exfoliated tumor cell; BALF: bronchoalveolar lavage fluid; CT: computerized tomography; PET: positron emission tomography; LDCT: low-dose computerized tomography; ATS: American Thoracic Society; ACCP: American College of Chest Physicians; SEM: scanning electron microscopy; BAL: bronchoalveolar lavage; HE staining: hematoxylin-eosin staining; NEG: negative for neoplastic cells; SCC: squamous cell carcinoma; ADC: adenocarcinoma; SCLC: small cell lung cancer; SUS: suspected for neoplastic cells; CTD-ILD: connective tissue disease-associated interstitial lung disease; IPF: idiopathic pulmonary fibrosis; AI: artificial intelligence; ICC: immunocytochemistry; IF: immunofluorescence; FISH: fluorescent in situ hybridization; CTC: circulating tumor cell; ctDNA: circulating tumor DNA.

Acknowledgements

This research is funded by the National Key R & D Program of China (Grant No. 2019YFC200056), National Natural Science Foundation of China (Grant No. 61904004), the Beijing Natural Science Foundation (Grant No. 4172028), the Postdoctoral Science Foundation of China (Grant Nos. 2018M631261 and 2019T120018), the Seeding Grant for Medicine and Information Sciences awarded by Peking University (Grant No. BMU2018M1003), the Cross Clinical Trial Foundation (Grant No. 2018CR34) and the Scientific Research Seed Fund (2018SF007) of Peking University First Hospital. This work is supported by the 111 Project (B18001). We express our gratitude to all patients who contributed BALF samples. We address our thanks to the nurses from the Department of Respiratory and Critical Care Medicine, Peking University First Hospital, for help with the BALF sample collection. Last but not the least, we also want to thank the staffs from the National Key Laboratory of Science and Technology on Micro/Nano Fabrication for their help with the filter preparation.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7-34.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115-32.
4. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: e142S-e165S.
5. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: e211S-e265S.
6. Wiener RS, Gould MK, Arenberg DA, Au DH, Fenig K, Lamb CR, et al. An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice. Am J Respir Crit Care Med. 2013; 189: 881-91.
7. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
8. Wang X, Liu H, Shen Y, Li W, Chen Y, Wang H. Low-dose computed tomography (LDCT) versus other cancer screenings in early diagnosis of lung cancer: A meta-analysis. Medicine. 2018; 97: e11233.
9. Shigeyasu K, Toden S, Zumbwall TJ, Okugawa Y, Goel A. Emerging role of microRNAs as liquid biopsy biomarkers in gastrointestinal cancers. Clin Cancer Res. 2017; 23: 2991-9.
10. Heitzer E, Haeque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsy in genomics-driven oncology. Nat Rev Genet. 2019; 20: 71-88.
11. De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019; 40: 172-86.
12. Marrugo-Ramirez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018; 19: 2877.
13. Poletti V, Poletti G, Murer B, Saragoni L, Chilosi M. Bronchoalveolar lavage in malignancy. Semin Respir Crit Care Med. 2007; 28: 534-45.
14. Springmeyer SC, Hackman R, Carlson JJ, McClellan JE. Bronchiolo-alveolar cell carcinoma diagnosed by bronchoalveolar lavage. Chest. 1983; 83: 278-9.
15. Hoda RS, VandenBussche C, Hoda SA. Liquid-based specimen collection, preparation, and morphology. In: Diagnostic liquid-based cytology. Berlin: Springer; 2017: 1-12.

16. Zhang X, Kuang Y, Zhang Y, He K, Lechtzin N, Zeng M, et al. Shifted focus of bronchoalveolar lavage in patients with suspected thoracic malignancy: an analysis of 224 cases. J Thorac Dis. 2016; 8: 3245-54.

17. Onghenaart P, Onghunnante S, Ejomoritutal W, Charoenratanakul S, Tsichekuna J, Younghaiyaidu P, et al. Diagnostic value of bronchoalveolar lavage and postbronchoscopic cytology in peripheral lung cancer. Respirology. 1998; 3: 131-7.

18. Binesh F, Firdehghian A, Mirjalili MR, Samet M, Maumord ZA, Akhtava A. Comparative assessment of the diagnostic value of transbronchial biopsy and bronchoalveolar lavage fluid cytology in lung cancer. Asian J Cancer Prev. 2015; 16: 261-4.

19. Hoda RS, VandenBussche C, Hoda SA. Respiratory exfoliative cytology. In: Diagnostic liquid-based Cytology. Berlin: Springer; 2017: 105-117.

20. Nagraath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ullks L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 456: 1235-9.

21. Chen JF, Zhu Y, Lu YT, Hodara E, Hous S, Agopian VG, et al. Clinical applications of NanoVelcro rare-cell assays for detection and characterization of circulating tumour cells. Theranostics 2016; 6:1425-1439.

22. Reategui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, et al. Tunable nanostructured coating for the capture and selective release of viable circulating tumour cells. Adv Mater. 2015; 27: 1593-9.

23. Jiang X, Wong KH, Khanhel AH, Zeinali M, Reategui E, Phillips MJ, et al. Microfluidic isolation of platelet-covered circulating tumor cells. Lab Chip. 2017; 17: 3498-503.

24. Warkiani ME, Khou BL, Wu L, Tay AK, Bhagat AA, Han J, et al. Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics. Nat Protoc. 2011; 6: 134-48.

25. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miymato DT, Brachtel D, et al. Inertial focusing for tumor antigen-dependent and antigen-independent sorting of rare circulating tumor cells. Sci Transl Med. 2013; 5: 179ra47-rae7.

26. Yan S, Zhang J, Yuan D, Li W. Hybrid microfluidics combined with active and passive approaches for continuous cell separation. Electrophoresis. 2015; 38: 238-49.

27. Pang L, Shen S, Ma C, Ma T, Zhang R, Tian C, et al. Deformability and size-based cancer cell separation using an integrated microfluidic device. Analyst. 2015; 140: 7335-46.

28. Gasconye PR, Shil S. Isolation of circulating tumor cells by dielectrophoresis. Cancers. 2014; 6: 545-79.

29. Choi H, Kim KB, Jeon CS, Hwang I, Lee S, Kim HK, et al. A label-free DC impedance-based microcytometer for suspending rare cancer cell counting. Lab Chip. 2013; 13: 970-7.

30. Sarisoglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015; 12: 685-91.

31. Hricvica GE, Parveen Z, Wagner C, Janning M, Quiddle J, Stein A, et al. A novel microfluidic platform for size and deformability-based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer. 2016; 138: 2894-904.

32. Zhou MD, Haos S, Williams AJ, Harouaka RA, Schrand B, Rawal S, et al. Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells. Sci Rep. 2014: 4: 7392.

33. Kang YT, Doh I, Byun J, Chang HJ, Cho YH. Label-free rapid viable enrichment of circulating tumor cell by photosensitive polymer-based microfilter device. Theranostics. 2017;7: 3179-91.

34. Fan X, Jia C, Yang J, Li G, Mao H, Jin Q, et al. A microfluidic chip integrated with a high-density PDMS-based microfiltration membrane for rapid isolation and detection of circulating cells. Biosens Bioelectron. 2015; 71: 380-6.

35. Liu Yi, Li T, Xu M, Zhang W, Xiong Y, Nie L, et al. A high-throughput liquid biopsy for rapid cell separation from large-volume samples. Lab Chip. 2019; 19: 68-78.

36. Liu Y, Xu H, Dai W, Li H, Wang W. 2.5-Dimensional Parylene C micro pore array with a large area and a high porosity for high-throughput particle and cell separation. Microsys Nanoeng. 2018: 4: 13.

37. Zydzowiec S, Yeldandi A and Raparia K. Cytology of the lung. In: Nayar R, Ed. Diagnostic Liquid-Based Cytology. Berlin: Springer; 2017: 105-117.

38. Sim SY, Choi YR, Lee JH, Lim JM, Lee SE, Kim KP, et al. In-depth proteomic analysis of human bronchoalveolar lavage fluid toward the biomarker discovery for lung cancers. Proteomics Clin Appl. 2019: 13: e1800028.

39. Appel JH, Ren H, Sin ML, Liao JC, Chae J. Rapid bladder cancer cell detection from clinical urine samples using an ultra-thin silicone membrane. Analyst. 2016; 141: 652-60.

40. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14: 623-31.

41. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystone A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011; 29: 1556-63.

42. Liang W, Zhao Y, Huang W, Gao Y, Xu W, Tao J, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019: 9; 8: 1562-70.

43. Lim M, Kim CJ, Suknara V, Kim MI, Cho YK. Liquid biopsy in lung cancer: clinical applications of circulating biomarkers (CTCs and ctDNA). Micromachines. 2018: 9; 10: 538.

44. Zsada P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019; 25: 1928-37.

45. Carvalho AS, Cuco CM, Lavareda C, Miguel F, Ventura M, Almeida S, et al. Bronchoalveolar lavage proteomics in patients with suspected lung cancer. Sci Rep. 2017; 7: 42180.

46. Cao C, Chen ZB, Sun SF, Yu YM, Ding QL, Deng ZC. Evaluation of VEGF-C and tumor markers in bronchoalveolar lavage fluid for lung cancer diagnosis. Sci Rep. 2013; 3: 3473.

47. Hennings A, Gribbin ME, Lynch V, Clynes M, Morgan R, Dowling P. Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry. BBA Clin. 2017; 7: 97-104.

48. Sim SY, Choi YR, Lee JH, Lim JM, Lee SE, Kim KP, et al. In-depth proteomic analysis of human bronchoalveolar lavage fluid toward the biomarker discovery for lung cancers. Proteomics Clin Appl. 2019: 13: e1800028.